Midwest Trust Co Grows Holdings in AbbVie Inc. $ABBV

Midwest Trust Co increased its holdings in AbbVie Inc. (NYSE:ABBV) by 0.9% in the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 489,495 shares of the company’s stock after acquiring an additional 4,215 shares during the quarter. AbbVie comprises about 1.4% of Midwest Trust Co’s investment portfolio, making the stock its 15th biggest holding. Midwest Trust Co’s holdings in AbbVie were worth $123,177,000 at the end of the most recent quarter.

A number of other large investors also recently bought and sold shares of ABBV. LFG Wealth Partners LLC boosted its stake in AbbVie by 13.9% during the second quarter. LFG Wealth Partners LLC now owns 7,864 shares of the company’s stock worth $1,979,000 after acquiring an additional 961 shares in the last quarter. Golden Reserve Retirement LLC increased its stake in shares of AbbVie by 102.2% during the second quarter. Golden Reserve Retirement LLC now owns 3,686 shares of the company’s stock valued at $927,000 after purchasing an additional 1,863 shares in the last quarter. Investment Research Partners LLC increased its stake in shares of AbbVie by 5.7% during the second quarter. Investment Research Partners LLC now owns 5,081 shares of the company’s stock valued at $1,279,000 after purchasing an additional 273 shares in the last quarter. 71 West Capital Partners lifted its holdings in shares of AbbVie by 45.1% during the second quarter. 71 West Capital Partners now owns 12,555 shares of the company’s stock valued at $3,159,000 after purchasing an additional 3,901 shares during the last quarter. Finally, Cascade Financial Partners LLC lifted its holdings in shares of AbbVie by 1.9% during the second quarter. Cascade Financial Partners LLC now owns 2,524 shares of the company’s stock valued at $635,000 after purchasing an additional 48 shares during the last quarter. 70.23% of the stock is owned by hedge funds and other institutional investors.

Key AbbVie News

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: New lung-cancer data supports AbbVie’s long-term growth strategy. At the 2026 World Conference on Lung Cancer, AbbVie presented clinical, translational and real-world data for investigational programs including ABBV-1480, telisotuzumab adizutecan and ABBV-706 across non-small cell and small cell lung cancer. The updates highlight potential future oncology revenue sources beyond the company’s established immunology portfolio. AbbVie WCLC 2026 announcement
• Positive Sentiment: AbbVie is broadening its aesthetics pipeline. The company has initiated a Phase 2 study evaluating a treatment for forehead lines, adding another potential product to its aesthetics franchise and reinforcing efforts to diversify growth. AbbVie aesthetics pipeline update
• Neutral Sentiment: AbbVie’s relatively low market correlation reflects its defensive pharmaceutical revenue base. Investor performance is driven more by product demand, reimbursement and payer dynamics than by broad equity-market movements. This may help explain the stock’s resilience, but the article does not identify a new earnings catalyst. What Moves AbbVie Stock
• Neutral Sentiment: AbbVie recently reported quarterly EPS and revenue above consensus, with revenue rising 10.2% year over year, and guided to third-quarter EPS of $3.84–$3.88. Analysts’ average price target of $275.73 remains above the current trading level, although the stock’s elevated valuation raises expectations. AbbVie stock and earnings information
• Negative Sentiment: An early end to a long-term emraclidine schizophrenia study introduces uncertainty. Investors may question the implications for AbbVie’s neuroscience pipeline and the program’s development prospects until the company provides additional details. AbbVie emraclidine study update
• Negative Sentiment: An executive vice president sold approximately $8.18 million of ABBV shares, reducing his position by about 30.5%. The sale may weigh modestly on sentiment, although insider transactions can reflect personal financial planning rather than a change in business outlook. AbbVie insider sale

Insider Activity at AbbVie

In related news, EVP Nicholas Donoghoe sold 32,710 shares of AbbVie stock in a transaction dated Friday, August 14th. The stock was sold at an average price of $250.00, for a total value of $8,177,500.00. Following the completion of the sale, the executive vice president directly owned 74,430 shares in the company, valued at approximately $18,607,500. This trade represents a 30.53% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 0.06% of the stock is owned by company insiders.

Analyst Ratings Changes

Several analysts recently weighed in on the company. Erste Group Bank upgraded AbbVie from a “hold” rating to a “buy” rating in a research note on Wednesday, August 5th. BMO Capital Markets lifted their price objective on AbbVie from $258.00 to $300.00 and gave the company an “outperform” rating in a research note on Monday, July 13th. Piper Sandler boosted their target price on AbbVie from $298.00 to $303.00 and gave the stock an “overweight” rating in a report on Thursday. Bank of America increased their target price on AbbVie from $234.00 to $276.00 and gave the stock a “buy” rating in a research note on Friday, July 10th. Finally, Barclays raised their price target on AbbVie from $275.00 to $300.00 and gave the company an “overweight” rating in a report on Wednesday, July 29th. Two equities research analysts have rated the stock with a Strong Buy rating, nineteen have given a Buy rating and five have issued a Hold rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $275.95.

AbbVie Stock Up 0.2%

Shares of NYSE ABBV opened at $265.62 on Monday. The firm has a market cap of $469.29 billion, a P/E ratio of 75.03, a PEG ratio of 0.88 and a beta of 0.30. AbbVie Inc. has a twelve month low of $190.75 and a twelve month high of $267.47. The company has a 50 day moving average of $248.48 and a 200 day moving average of $227.50.

AbbVie (NYSE:ABBV) last issued its earnings results on Friday, July 31st. The company reported $3.65 EPS for the quarter, beating the consensus estimate of $3.61 by $0.04. The business had revenue of $16.99 billion for the quarter, compared to the consensus estimate of $16.80 billion. AbbVie had a negative return on equity of 422.07% and a net margin of 9.80%.The company’s revenue was up 10.2% compared to the same quarter last year. During the same period last year, the business posted $2.97 EPS. AbbVie has set its Q3 2026 guidance at 3.840-3.880 EPS. As a group, equities analysts expect that AbbVie Inc. will post 14.06 earnings per share for the current fiscal year.

AbbVie Announces Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Friday, August 14th. Investors of record on Wednesday, July 15th were given a dividend of $1.73 per share. The ex-dividend date of this dividend was Wednesday, July 15th. This represents a $6.92 annualized dividend and a dividend yield of 2.6%. AbbVie’s dividend payout ratio (DPR) is 195.48%.

About AbbVie

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.